Myriad Genetics
Myriad Genetics' revenue fell 1.6% to $824 million in fiscal 2025. Its operating margin was −47.0%, down from −14.7% a year earlier. Free cash flow was −$14 million. The diluted share count rose 2.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Myriad Genetics does
Myriad Genetics develops and sells molecular tests that read a person's DNA or tumor for genetic information. The tests assess the risk of developing a disease or how it may progress, and help guide treatment. It works across three areas: cancer care, prenatal health and mental health.
In cancer, it offers hereditary cancer testing that covers eleven common cancer types, including breast, ovarian, colorectal, prostate, lung and skin. It also sells a test called HRD, used to choose cancer therapy, and Precise MRD, which looks for small amounts of cancer remaining after treatment. The company says it plans to add more comprehensive tumor profiling tests through its own development and partnerships.
Myriad says it aims to grow its prenatal and mental health revenue at or above market growth, and to expand its tests across cancer care. It sells mostly through its commercial reach in community medicine, serving doctors and patients. Its revenue depends on insurers and government payers covering and paying for its tests.
Its biggest risks, as it describes them
- It may not be able to earn enough from its existing tests or develop new ones to be profitable.
- Its strategic plan may not deliver the expected results or revenue growth.
- If government and other payers do not cover its tests and pay enough, its revenue will suffer.
- Its debt covenants limit its operations and finances, and it may need more funding.
- It has faced securities class actions and shareholder suits, and may face product or professional liability claims.
Income statement
From fiscal 2016 to 2019, earnings per share fell 66.5% a year and net income 66.0% a year, as new shares raised the share count by 4% and diluted each share's earnings. Myriad Genetics then lost money in fiscal 2020, 2021, 2022, 2023, 2024 and 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 399 | 170 | 141 | 102 | 150 |
| Debt incl. finance leases | 0 | 0 | 38 | 40 | 120 |
| Net debt (negative means net cash) | −399 | −170 | −102 | −63 | −30 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | 0.1x | 0.1x | 0.3x |
| Interest coverage | −28.9x | −43.9x | −88.8x | −44.1x | −36.9x |
| Current ratio | 2.4x | 2.0x | 2.0x | 1.8x | 2.5x |
| Quick ratio | 2.3x | 1.9x | 1.9x | 1.6x | 2.3x |
Cash flow
Projections
Project Myriad Genetics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Myriad Genetics reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 4 of 9 | 5 of 9 |
| Rule of 40 | −12.1% | 7.9% | −3.2% |
| Altman Z'' | −0.13 | −0.10 | −5.88 |
| Accruals ratio | −13.0% | −10.9% | −42.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Pass |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 3 of 9 | 4 of 9 | 5 of 9 |
Compare
Put Myriad Genetics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Myriad Genetics | FY25 | −1.6% | −47.0% | −1.7% | −62.6% | — | 5 | |
| NeoGenomics Laboratories | FY25 | 10.1% | −15.9% | −3.0% | −8.8% | — | 5 | Compare |
| Pennant Group | FY25 | 36.3% | 5.5% | 3.8% | 9.3% | 2.6x | 5 | Compare |
| CorVel | FY26 | 7.0% | — | 11.5% | — | — | — | Compare |
| Sotera Health | FY25 | 5.7% | — | 12.8% | 6.7% | — | 7 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 754 | 771 | 744 | 851 | 639 | 691 | 678 | 753 | 838 | 824 |
| Revenue growth | 4.2% | 2.3% | −3.6% | 14.4% | −25.0% | 8.1% | −1.8% | 11.0% | 11.2% | −1.6% |
| Gross profit | 621 | 626 | — | — | — | — | 476 | 517 | 585 | 577 |
| Research and development | 71 | 74 | 71 | 86 | 77 | 82 | 85 | 89 | 113 | 107 |
| Operating income | 153 | 44 | 122 | 8 | −232 | −190 | −141 | −257 | −124 | −387 |
| Net income | 117 | 17 | 133 | 5 | −200 | −27 | −112 | −263 | −127 | −366 |
| Diluted EPS (US$) | 1.60 | 0.25 | 1.85 | 0.06 | −2.69 | −0.35 | −1.39 | −3.18 | −1.41 | −3.95 |
| Diluted shares (millions) | 73 | 69 | 72 | 76 | 74 | 78 | 81 | 83 | 91 | 93 |
| Cash flow | ||||||||||
| Cash from operations | 166 | 106 | 116 | 84 | 61 | 19 | −106 | −111 | −9 | 2 |
| Capital expenditure | 5 | 6 | 8 | 9 | 10 | 18 | 45 | 63 | 19 | 16 |
| Free cash flow | 161 | 100 | 108 | 75 | 50 | 1 | −152 | −174 | −28 | −14 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 163 | 32 | 0 | 50 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 37 | 216 | 0 | 278 | 0 | 0 | 57 | 0 | 0 | 0 |
| Stock-based compensation | 32 | 30 | 27 | 34 | 25 | 36 | 38 | 41 | 50 | 35 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 159 | 151 | 181 | 192 | 255 | 399 | 170 | 141 | 102 | 150 |
| Debt incl. finance leases | — | 99 | 9 | 234 | 224 | 0 | 0 | 38 | 40 | 120 |
| Total assets | 880 | 1,209 | 1,175 | 1,563 | 1,405 | 1,321 | 1,199 | 1,146 | 1,028 | 707 |
| Total liabilities | 132 | 441 | 209 | 474 | 486 | 353 | 313 | 363 | 326 | 339 |
| Shareholders' equity | 740 | 768 | 966 | 1,089 | 918 | 968 | 886 | 783 | 701 | 368 |
| Margins and ratios | ||||||||||
| Gross margin | 82.4% | 81.2% | — | — | — | — | 70.2% | 68.6% | 69.9% | 69.9% |
| Operating margin | 20.4% | 5.7% | 16.4% | 0.9% | −36.3% | −27.6% | −20.7% | −34.2% | −14.7% | −47.0% |
| Net margin | 15.6% | 2.3% | 17.9% | 0.5% | −31.2% | −3.9% | −16.5% | −35.0% | −15.2% | −44.4% |
| Free cash flow margin | 21.4% | 13.0% | 14.4% | 8.8% | 7.9% | 0.1% | −22.4% | −23.1% | −3.3% | −1.7% |
| Rule of 40 (growth + FCF margin) | 25.6% | 15.3% | 10.9% | 23.3% | −17.1% | 8.2% | −24.1% | −12.1% | 7.9% | −3.2% |
| Return on capital | — | — | 16.1% | 0.6% | −18.1% | −20.7% | −17.3% | −29.1% | −14.8% | −62.6% |
| Return on equity | 16.7% | 2.3% | 15.4% | 0.5% | −19.9% | −2.9% | −12.1% | −31.6% | −17.1% | −68.5% |
| Return on assets | 14.2% | 1.7% | 11.2% | 0.3% | −13.4% | −2.0% | −8.9% | −22.4% | −11.7% | −42.2% |
| Net debt to EBITDA | — | −0.6x | −1.0x | 0.5x | — | — | — | — | — | — |